Improved Language Acquisition With Levodopa
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the non-daily administration of levodopa is effective in boosting semantic language acquisition in healthy subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: levodopa |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Improved Language Acquisition With Levodopa |
- Boost in language learning success through levodopa compared to placebo
- Stability of language learning success after one month
| Estimated Enrollment: | 20 |
| Study Start Date: | March 2003 |
| Estimated Study Completion Date: | December 2003 |
Our prior work using a between-subject design shows that daily administration of d-amphetamine or the dopamine precursor levodopa over the course of five days markedly improves word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether the effect can be replicated using a within-subject design, with administration of levodopa and placebo on alternate days for a total period of 10 days.
The expected scientific results will strengthen the basis for transferring neuromodulatory interventions from the laboratory to stroke patients with language dysfunctions. Because of the heterogeneity of stroke patients, only a within-subject design can be used to probe the effects of pharmacological adjuncts to language therapy.
Eligibility| Ages Eligible for Study: | 20 Years to 35 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy subjects
- 20-35 years old
- Right handedness
Exclusion Criteria:
- Neurological/psychiatric/metabolic/cardiac disorders
- Asthma
- Known allergic reactions to one of the experimental drugs
- Other drugs affecting the central nervous system
- Leisure drug ingestion during the past 4 weeks (urine test)
- Smoking cessation during the past 2 weeks
- > 6 cups of coffee or energy drinks per day
- > 10 cigarettes per day
- > 50 grams of alcohol per day
Contacts and Locations| Germany | |
| Dept. of Neurology, University Hospital Muenster | |
| Muenster, Nordrhein-Westfalen, Germany, 48129 | |
| Study Director: | Caterina Breitenstein, PhD | Dept. of Neurology, University of Muenster, Germany |
| Study Chair: | Stefan Knecht, MD | Dept. of Neurology, University of Muenster, Germany |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00103805 History of Changes |
| Other Study ID Numbers: | KS-LD_01 |
| Study First Received: | February 14, 2005 |
| Last Updated: | September 7, 2006 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by University Hospital Muenster:
|
language acquisition plasticity stroke recovery associative learning |
Additional relevant MeSH terms:
|
Levodopa Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses |
Pharmacologic Actions Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 19, 2013